These stocks were recommended by Smarter Analyst’s newsletter BioPortfolio, a standout investment resource that allows each subscriber to see the newsletter’s whole history- and the only newsletter out there that makes that an available option for its readers. The BioPortfolio cares less about hyping success tales and more about pinpointing just what you could have gained had you invested by the sentiment-based model, and not isolated biotech stock choices. Thanks to Smarter Analyst’s advanced natural language processing algorithms that know how to detect in real-time millions of opinions, from key analysts to leading bloggers, the BioPortfolio was designed to help its readers figure out what the best trades of the game are today. Subscribers get to uncover what are the three top biotech stock trades of the week (two long and one short); all part of BioPortfolio’s whiz system.
Let’s explore why Apollo Endosurgery Inc (NASDAQ:APEN), Avadel Pharmaceuticals plc (NASDAQ:AVDL), and Beigene Ltd (ADR) (NASDAQ:BGNE) are the hot biotech stocks Smarter Analyst’s BioPortfolio has spotlighted as captivating gainers to follow:
Apollo has been a mover and shaker to watch, racking up 15% in share growth since the stock was mentioned in BioPortfolio on September 28th. Why is Wall Street optimistic on this Austin-based medical device maker?
Keep in mind, Apollo presented at the Cantor Fitzgerald Global Healthcare Conference at the end of September, and the month before, the healthcare firm presented 20-year outcomes data for its LAP-BAND (adjustable gastric band) System at the 22nd World Congress of the International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO) in London, England. The long-term outcomes bode positively for Apollo, bolstering proof that its LAP-BAND is not only safe, but also an effective procedure that brings to the table sustained, medically relevant weight loss results.
Avadel has been gaining 13% since the stock was highlighted in BioPortfolio‘s September 28th newsletter. The biotech firm recently scheduled a presentation to showcase a clinical evaluation of its nocturia drug Noctiva(which was once called “SER120”). Designed to treat the symptoms of nocturnal polyuria for patients with concomitant overactive bladder (OAB), Avadel’s drug garnered the FDA green light in March, offering much-needed relief to adults who take two or more trips each night to urinate. Noctiva’s data presentation will take place at The American Urogynecologic Society’s Annual Scientific Meeting in an oral poster presentation at Pelvic Floor Disorders (PFD) Week this year.
Ever since Beigene released promising initial Phase 1 data for its immunotherapy BGB-A317 in Chinese patients suffering from advanced solid tumors. BGNE’s investigational anti-PD-1 antibody has the Street excited, as between the BioPortfolio’s September 28th edition and now, the biotech player has amassed nearly 4% in trading gains.
The biotech firm’s team presented at the 20th Annual Meeting of the Chinese Society of Clinical Oncology (CSCO) in Xiamen, China, pointing to data that indicates the Chinese cancer drug maker’s treatment was well-tolerated by patients in the study. In fact, BGNE’s asset pointed to reassuring sparks of evidence that might mean the treatment lead to anti-tumor activity in a Chinese trial population where patients were afflicted with advanced solid tumors. Patients in the Phase 1 part of the trial were taking 200 mg of BGB-A317 once every three weeks.
Worthy of note, BeiGene and Celgene have a worldwide strategic deal for BGB-A317 for solid tumors, where BGNE holds onto exclusive rights to the immunotherapy asset in China.